Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Abstract Background Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits...

Full description

Bibliographic Details
Main Authors: Lu Xie, Wei Guo, Ye Wang, Taiqiang Yan, Tao Ji, Jie Xu
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
Apatinib
Tyrosine-kinase inhibitor
Osteosarcoma
Chondrosarcoma
Soft-tissue sarcoma
Ewing sarcoma
Online Access:http://link.springer.com/article/10.1186/s12885-018-4303-z

Similar Items

Similar Items